CLINUVEL PHARMACEUTICALS LTD

Home
Australia
Melbourne, VIC
CLINUVEL PHARMACEUTICALS LTD

We are a global specialty pharmaceutical group focused on developing and commercialising treatments

29/09/2025

CLINUVEL today announced that it is advancing new sustained-release liquid drug formulations in a preclinical program evaluating various drug release profiles.

A decade of investment in fundamental research & development in CLINUVEL’s fully-owned Singaporean laboratories (VALLAURIX) has provided positive, consistent results demonstrating the potential for depot formulations to extend the duration of release of peptide drugs.

Learn more in the announcement here:https://www.clinuvel.com/wp-content/uploads/2025/09/20250929-clinuvel-advances-new-formulations-in-preclinical-program.pdf

24/09/2025

Patient support groups can make a life-changing difference for people living with vitiligo, providing community, encouragement, and a safe space to share experiences.

We’re proud to welcome Tonja Johnson, founder of the Beautifully Unblemished Vitiligo Support Group to the CLINUVEL podcast as our first external guest.

In this episode, she shares her inspiring journey, the importance of connection and how her work continues to empower others navigating life with vitiligo.

Listen here: https://brnw.ch/21wW2Kc

23/09/2025

CLINUVEL is pleased to share that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on amending the label for CLINUVEL’s photoprotective drug SCENESSE® (afamelanotide), enabling adult erythropoietic protoporphyria (EPP) patients to receive treatment every two months.

The label removes a recommended maximum annual dose of four implants per year and harmonises treatment posology in Europe with the USA, where patients receive year-round therapy.

Learn more here: https://brnw.ch/21wW0ux

22/09/2025

CLINUVEL’s Annual General Meeting is set to take place on 17 October 2025. The meeting provides an opportunity to vote on important resolutions and support the strategic direction of the Company.

The Board of Directors encourages all shareholders to submit their directed proxy votes in advance of the AGM.

It is important that beneficial shareholders follow the instructions of their custodian or broker on procedures for voting.

View the meeting details and explanatory memorandum here: https://brnw.ch/21wVYvf

20/09/2025

The 4th Annual Vitiligo Awareness Walk takes place in Tampa today.
CLINUVEL is honoured to support the Beautifully Unblemished Vitiligo Support Group with this event that unites the vitiligo community, helping highlight the challenges faced by people living with the autoimmune condition.

Over the past three years, over five hundred people have joined the walk with increased participation and we look forward to seeing the impact of this year’s event in raising awareness and strengthening support for those affected.

19/09/2025

Three new patient cases demonstrating the efficacy of afamelanotide in vitiligo patients have been presented to the European Academy of Dermatology and Venereology (EADV) conference in Paris, France.

The three patients, treated at a single reference hospital in La Reunion, France, all completed treatment in CLINUVEL’s ongoing CUV105 study, receiving seven afamelanotide implants and up to 40 narrowband ultraviolet B (NB-UVB) phototherapy sessions.

Learn more here: https://brnw.ch/21wVU7M

18/09/2025

CLINUVEL proudly hosted an in-person event inviting European porphyria experts to share data and key learnings on erythropoietic protoporphyria (EPP), engaging the community and highlighting the rare metabolic disorder that impacts approximately 10,000 people globally. This was the sixth meeting of its kind organised by CLINUVEL and the first post-pandemic.

Collaborating directly with experts that treat patients every day allows us to gain valuable insights into the challenges of EPP and understand the positive impact we are making on the lives of those affected by the rare disorder. Our team works tirelessly to expand treatment access to those who need it the most, engaging with regulatory bodies worldwide to facilitate this goal.

The meeting also discussed the continuation of our clinical program investigating a potential treatment for variegate porphyria.

With this event, we hope to further the meaningful advancements in care for people living with porphyria around the world, providing the treatment they deserve to improve their quality of life.

$CUV.AX $CLVLY

17/09/2025

The CLINUVEL team has travelled to Paris for the 2025 EADV congress.

The Congress is an international meeting focused on dermatology and venereology, providing a platform for researchers, clinicians, and industry professionals to exchange knowledge, network, and present their latest research findings.

$CUV.AX $CLVLY

16/09/2025

The latest CLINUVEL podcast episode is now available on our YouTube channel.

Dr Dennis Wright, CLINUVEL’s Chief Scientific Officer, joins Sarah Mawson to discuss the history of the development of afamelanotide, the first ever approved treatment for erythropoietic protoporphyria (EPP).

Listen to the podcast here: https://brnw.ch/21wVNbj

09/09/2025

Did you know… there are 31 nationalities represented amongst the CLINUVEL team?

Having a diversity of minds from around the world allows CLINUVEL to explore different ways of thinking and innovative approaches to address unmet treatment needs for a range of medical conditions.

Learn more about CLINUVEL, our future goals and achievements in our 2025 Annual Report here: https://annualreport.clinuvel.com/

$CUV.AX $CLVLY

05/09/2025

The United States of America provides a key opportunity for CLINUVEL, with patient populations that may benefit from our innovative products.

CLINUVEL has taken considerable steps to build a commercial footprint in the US through Specialty Centers for the treatment of EPP as well as the recently announced plans to upgrade its ADR to a Level II program listed on the Nasdaq.

Learn more about our plans for US expansion in our 2025 Annual Report: https://annualreport.clinuvel.com/

$CUV.AX $CLVLY

01/09/2025

2025 has been an impactful year for CLINUVEL with a significant presence at the American Academy of Dermatology Annual Meeting, strong financial performance and recruitment goal achievements for our CUV105 vitiligo clinical trial.

Learn more from our Managing Director Dr Philippe Wolgen in CLINUVEL’s annual report: https://annualreport.clinuvel.com/

$CUV.AX $CLVLY

Address

535 Bourke Street
Melbourne, VIC
3000

Telephone

+61396604900

Website

https://www.clinuvel.com/

Alerts

Be the first to know and let us send you an email when CLINUVEL PHARMACEUTICALS LTD posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to CLINUVEL PHARMACEUTICALS LTD:

Shortcuts

Featured

Hands-On Laser Cosmetic Clinic
347 Somerville Road, Yarraville

Want your practice to be the top-listed Clinic in Melbourne?